(Q33237201)

24 July 2017

Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects (English)

1 reference

24 July 2017

0 references

0 references

5

Thomas Beach

1 reference

24 July 2017

Eduardo M Castaño

1

1 reference

24 July 2017

Alex E Roher

series ordinal

2

1 reference

24 July 2017

Chera L Esh

series ordinal

3

1 reference

24 July 2017

Tyler A Kokjohn

series ordinal

4

1 reference

24 July 2017

1 March 2006

1 reference

24 July 2017

Neurological Research

1 reference

24 July 2017

28

1 reference

24 July 2017

155-163

1 reference

24 July 2017

2

1 reference

Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis.

24 July 2017

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

The diagnosis of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

The cerebral expression of plasma protein genes in different species

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Choroid plexus ageing of the brain and Alzheimer s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Curly fiber and tangle-like inclusions in the ependyma and choroid plexus--a pathogenetic relationship with the cortical Alzheimer-type changes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Intrathecal inflammation precedes development of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Dynamics of brain-derived proteins in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Apolipoprotein E isoforms and apolipoprotein AI protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Microglial functions and proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

In vitro processing of amyloid precursor protein by cathepsin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Extracellular phosphorylation converts pigment epithelium-derived factor from a neurotrophic to an antiangiogenic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Pigment epithelium–derived factor regulates the vasculature and mass of the prostate and pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Regulation of factors controlling angiogenesis in liver development: a role for PEDF in the formation and maintenance of normal vasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

PEDF: Raising both hopes and questions in controlling angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Only amyloidogenic intermediates of transthyretin induce apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Serum amyloid A protein, albumin and prealbumin in Alzheimer's disease and in demented patients with Down's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Biological activity and pathological implications of misfolded proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Cerebrospinal fluid inhibits Alzheimer beta-amyloid fibril formation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Transthyretin sequesters amyloid beta protein and prevents amyloid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

Amyloid beta protein and transthyretin, sequestrating protein colocalize in normal human kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F016164106X98035

21 January 2018

Identifiers

DOI

10.1179/016164106X98035

1 reference

24 July 2017

1 reference